ReviewWorld journal of gastroenterology2021
Screening for nonalcoholic fatty liver disease-when, who and how?
Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis.Lipids in health and disease · 2023Pooled it
- Attention-based graph neural network framework for non-invasive CAP score prediction in fatty liver disease via body modeling.Physical and engineering sciences in medicine · 2026Article
- Development and evaluation of machine learning models for predicting significant liver fibrosis stages: A retrospective analysis.Canadian liver journal · 2026Article
- The relationship between lipid accumulation products and non-alcoholic fatty liver disease among adults in the North of Iran: a cross-sectional study.BMC gastroenterology · 2025Article
- Prevalence of MASLD and Fibrosis Risk in Turkish Adults with Cardiometabolic Risk Factors: A Nationwide Multicenter Study (DAHUDER MASLD Study).Journal of clinical medicine · 2025Article
- Considerations and clinical utility of referral pathways for early detection of liver disease in at-risk populations.World journal of gastroenterology · 2025Review
- MOFI-FL, a novel score for detecting hepatic steatosis and predicting cardiometabolic mortality.Scientific reports · 2025Article
- Assessment of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Cross-sectional Study in Asymptomatic Individuals in Greater Vancouver.Journal of clinical and translational hepatology · 2025Article
- Sustainability of General Population Screening for Steatotic Liver Disease: A Proof-of-Concept Study.Healthcare (Basel, Switzerland) · 2025Article
- Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications.World journal of gastroenterology · 2024Article
- Metabolic Dysfunction-Associated Fatty Liver Disease and Fibrosis Status in Patients with Type 2 Diabetes Treated at Internal Medicine Clinics: Türkiye DAHUDER Awareness of Fatty Liver Disease (TR-DAFLD) Study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- Projected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States.Cancers · 2024Article
- Development and pilot evaluation of an evidence-based algorithm for MASLD (formerly NAFLD) management in primary care in Europe.Frontiers in medicine · 2024Article
- Prevalence of hepatic steatosis and fibrosis in apparently healthy airline pilots: A transient elastography study.Hepatology forum · 2024Article
- Transcriptomics of MASLD Pathobiology in African American Patients in the Washington DC AreaInternational journal of molecular sciences · 2023Article
- Non-alcoholic fatty liver disease in women - Current knowledge and emerging concepts.JHEP reports : innovation in hepatology · 2023Review
- A discrete choice experiment to elicit preferences for a liver screening programme in Queensland, Australia: a mixed methods study to select attributes and levels.BMC health services research · 2023Article
- Hypothyroidism and non-alcoholic fatty liver disease: A coincidence or a causal relationship?World journal of hepatology · 2023Review
- Clinical and Metabolic Characteristics of Hyperuricemia with Risk of Liver Fibrosis: A Cross-Sectional Study.Metabolites · 2022Article
- The Concept of Indeterminable NASH Inducted by Preoperative Diet and Metabolic Surgery: Analyses of Histopathological and Clinical Features.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is becoming a frequent liver disease, especially in patients with metabolic syndrome and especially in Western countries. Complications of NAFLD comprise progressive fibrosis, cirrhosis and hepatocellular carcinoma. NAFLD also represents an independent risk factor for cardiovascular disease, extrahepatic neoplasia and other organ damage, such as renal insufficiency. Given the epidemiological importance of the disease, new developments in specific treatment of the disease and the wide availability of noninvasive techniques in estimating steatosis and fibrosis, NAFLD should be subject to screening programs, at least in countries with a high prevalence of the disease. The review discusses prerequisites for screening, cost-effectiveness, current guideline recommendations, suitability of techniques for screening and propositions for the following questions: Who should be screened? Who should perform screening? How should screening be performed? It is time for a screening program in patients at risk for NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.